Venture
Affiliations
New York University
Technologies
Therapeutic
Indication
Basic Research
Clinical Research
Clinical Trials
Drug Discovery
Oncology
Orphan Diseases
Website
phdbiosciences.comWe are developing an enzyme inhibitor with pico-‐molar binding affinity and minimal toxicity as a once daily, oral therapeutic for the treatment of triple-‐negative breast cancer.
Nanomedics LLC Team: